|
1
|
Gross L: Intradermal immunization of C3H
mice against a sarcoma that originated in an animal of the same
line. Cancer Res. 3:326–333. 1943.
|
|
2
|
Prehn RT and Main JM: Immunity to
methylcholanthrene-induced sarcomas. J Natl Cancer Inst.
18:769–778. 1957.PubMed/NCBI
|
|
3
|
Hewitt HB, Blake ER and Walder AS: A
critique of the evidence for active host defence against cancer,
based on personal studies of 27 murine tumours of spontaneous
origin. Br J Cancer. 33:241–259. 1976. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Klein G and Klein E: Immune surveillance
against virus-induced tumors and nonrejectability of spontaneous
tumors: Contrasting consequences of host versus tumor evolution.
Proc Natl Acad Sci USA. 74:2121–2125. 1977. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Schreiber RD, Old LJ and Smyth MJ: Cancer
immunoediting: Integrating immunity's roles in cancer suppression
and promotion. Science. 331:1565–1570. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Chen F, Zhuang X, Lin L, Yu P, Wang Y, Shi
Y, Hu G and Sun Y: New horizons in tumor microenvironment biology:
Challenges and opportunities. BMC Med. 13:452015. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Swartz MA, Iida N, Yull FE, Roberts EW,
Sangaletti S, Wong MH, Yull FE, Coussens LM and DeClerck YA: Tumor
microenvironment complexity: Emerging roles in cancer therapy.
Cancer Res. 72:2473–2480. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Lindau D, Gielen P, Kroesen M, Wesseling P
and Adema GJ: The immunosuppressive tumour network: Myeloid-derived
suppressor cells, regulatory T cells and natural killer T cells.
Immunology. 138:105–115. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Obeid E, Nanda R, Fu YX and Olopade OI:
The role of tumor-associated macrophages in breast cancer
progression (Review). Int J Oncol. 43:5–12. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Shiga K, Hara M, Nagasaki T, Sato T,
Takahashi H and Takeyama H: Cancer-associated fibroblasts: Their
characteristics and their roles in tumor growth. Cancer (Basel).
7:2443–2458. 2015. View Article : Google Scholar
|
|
11
|
Anderson AC, Joller N and Kuchroo VK:
Lag-3, Tim-3, and TIGIT: Co-inhibitory receptors with specialized
functions in immune regulations. Immunity. 44:989–1004. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Smigiel KS, Srivastava S, Stolley JM and
Campbell DJ: Regulatory T-cell homeostasis: Steady-state
maintenance and modulation during inflammation. Immunol Rev.
259:40–45. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Ott PA, Hodi FS and Robert C: CTLA-4 and
PD-1/PD-L1blockade: New immunotherapeutic modalities with durable
clinical benefit in melanoma patients. Clin Cancer Res.
19:5300–5309. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Romano E and Romero P: The therapeutic
promise of disrupting the PD-1/PD-L1 immune checkpoint in cancer:
Unleashing the CD8 T cell mediated anti-tumor activity results in
significant, unprecedented clinical efficacy in various solid
tumors. J Immunother Cancer. 3:152015. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Mitchem JB, Brennan DJ, Knolhoff BL, Belt
BA, Zhu Y, Sanford DE, Belaygorod L, Carpenter D, Collins L,
Piwnica-Worms D, et al: Targeting tumor-infiltrating macrophages
decreases tumor-initiating cells, relieves immunosuppression and
improves chemotherapeutics responses. Cancer Res. 73:1128–1141.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
McAllister SS and Weinberg RA: The
tumour-induced systemic environment as a critical regulator of
cancer progression and metastasis. Nat Cell Biol. 16:717–727. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Hiratsuka S, Nakamura K, Iwai S, Murakami
M, Itoh T, Kijima H, Shipley JM, Senior RM and Shibuya M: MMP9
induction by vascular endothelial growth factor receptor-1 is
involved in lung-specific metastasis. Cancer Cell. 2:289–300. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Kaplan RN, Riba RD, Zacharoulis S, Bramley
AH, Vincent L, Costa C, MacDonald DD, Jin DK, Shido K, Kerns SA, et
al: VEGFR1-positive haematopoietic bone marrow progenitors initiate
the pre-metastatic niche. Nature. 438:820–827. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Hiratsuka S, Watanabe A, Aburatani H and
Maru Y: Tumour-mediated upregulation of chemoattractants and
recruitment of myeloid cells predetermines lung metastasis. Nat
Cell Biol. 8:1369–1375. 2006. View
Article : Google Scholar : PubMed/NCBI
|
|
20
|
Erler JT, Bennewith KL, Cox TR, Lang G,
Bird D, Koong A, Le QT and Giaccia AJ: Hypoxia-induced lysyl
oxidase is a critical mediator of bone marrow cell recruitment to
form the premetastatic niche. Cancer Cell. 15:35–44. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Kim S, Takahashi H, Lin WW, Descargues P,
Grivennikov S, Kim Y, Luo JL and Karin M: Carcinoma-produced
factors activate myeloid cells through TLR2 to stimulate
metastasis. Nature. 457:102–106. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Sceneay J, Chow MT, Chen A, Halse HM, Wong
CS, Andrews DM, Sloan EK, Parker BS, Bowtell DD, Smyth MJ and
Möller A: Primary tumor hypoxia recruits CD11b+/Ly6Cmed/Ly6G+
immune suppressor cells and compromises NK cell cytotoxicity in the
premetastatic niche. Cancer Res. 72:3906–3911. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Kang SY, Halvorsen OJ, Gravdal K,
Bhattacharya N, Lee JM, Liu NW, Johnston BT, Johnston AB, Haukaas
SA, Aamodt K, et al: Prosaposin inhibits tumor metastasis via
paracrine and endocrine stimulation of stromal p53 and Tsp-1. Proc
Natl Acad Sci USA. 106:12115–12120. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Granot Z, Henke E, Comen EA, King TA,
Norton L and Benezra R: Tumor entrained neutrophils inhibit seeding
in the premetastatic lung. Cancer Cell. 20:300–314. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Kurusu Y, Yamashita J and Ogawa M:
Detection of circulating tumor cells by reverse
transcriptasepolymerase chain reaction in patients with resectable
non-small-cell lung cancer. Surgery. 126:820–826. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Grabenbauer GG, Lahmer G, Distel L and
Niedobitek G: Tumor-infiltrating cytotoxic T cells but not
regulatory T cells predict outcome in anal squamous cell carcinoma.
Clin Cancer Res. 12:3355–3360. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Mellman I, Coukos G and Dranoff G: Cancer
immunotherapy comes of age. Nature. 480:480–489. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Friedl P and Alexander S: Cancer invasion
and the microenvironment: Plasticity and reciprocity. Cell.
147:992–1009. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Pietras K and Ostman A: Hallmarks of
cancer: Interactions with the tumor stroma. Exp Cell Res.
316:1324–1331. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Carlini MJ, De Lorenzo MS and Puricelli L:
Cross-talk between tumor cells and the microenvironment at the
metastatic niche. Curr Pharm Biotechnol. 12:1900–1908. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
McAllister SS, Gifford AM, Greiner AL,
Kelleher SP, Saelzler MP, Ince TA, Reinhardt F, Harris LN, Hylander
BL, Repasky EA and Weinberg RA: Systemic endocrine instigation of
indolent tumor growth requires osteopontin. Cell. 133:994–1005.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Curiel TJ, Coukos G, Zou L, Alvarez X,
Cheng P, Mottram P, Evdemon-Hogan M, Conejo-Garcia JR, Zhang L,
Burow M, et al: Specific recruitment of regulatory T cells in
ovarian carcinoma fosters immune privilege and predicts reduced
survival. Nat Med. 10:942–949. 2014. View
Article : Google Scholar
|
|
34
|
Jóźwicki W, Brożyna AA, Siekiera J and
Slominski AT: Frequency of CD4+CD25+Foxp3+ cells in peripheral
blood in relation to urinary bladder cancer malignancy indicators
before and after surgical removal. Oncotraget. 7:11450–11462.
2016.
|
|
35
|
Fogar P, Sperti C, Basso D, Sanzari MC,
Greco E, Davoli C, Navaglia F, Zambon CF, Pasquali C, Venza E, et
al: Decreased total lymphocyte counts in pancreatic cancer: An
index of adverse outcome. Pancreas. 32:22–28. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Ahmad SS, Akhtar K, Verma AK, Mallik AZ
and Siddiqui SA: Total peripheral lymphocyte count in malignant
tumors: An index of prognostication. J Med Sci. 12:24–28. 2012.
View Article : Google Scholar
|
|
37
|
Ray-Coquard I, Cropet C, Van Glabbeke M,
Sebban C, Le Cesne A, Judson I, Tredan O, Verweij J, Biron P,
Labidi I, et al: Lymphopenia as a prognostic factor for overall
survival in advanced carcinomas, sarcomas, and lymphomas. Cancer
Res. 69:5383–5391. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Fischer K, Voelkl S, Heymann J, Przybylski
GK, Mondal K, Laumer M, Kunz-Schughart L, Schmidt CA, Andreesen R
and Mackensen A: Isolation and characterization of human
antigen-specific TCR alpha beta+ CD4 (-)CD8- double-negative
regulatory T cells. Blood. 105:2828–2835. 2015. View Article : Google Scholar
|
|
39
|
Thomson CW, Lee BP and Zhang L:
Double-negative regulatory T cells: Non-conventional regulators.
Immunol Res. 35:163–178. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Priatel JJ, Utting O and Teh HS:
TCR/self-antigen interactions drive double-negative T cell
peripheral expansion and differentiation into suppressor cells. J
Immunol. 167:6188–6194. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Voelkl S, Gary R and Mackensen A:
Characterization of the immunoregulatory function of human TCR-αβ+
CD4-CD8- double-negative T cells. Eur J Immunol. 41:739–748. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Ligocki AJ and Niederkorn JY: Advances on
Non-CD4+Foxp3+T regulatory cells: CD8+, Type1, and double negative
t regulatory cells in organ transplantation. Transplantation.
99:1553–1559. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Sundaravaradan V, Mir KD and Sodora DL:
Double-negative T cells during HIV/SIV infections: Potential pinch
hitters in the T cell lineup. Curr Opin HIV AIDS. 7:164–171. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Young KJ, Kay LS, Phillips MJ and Zhang L:
Antitumor activity mediated by double-negative T cells. Cancer Res.
63:8014–8021. 2003.PubMed/NCBI
|
|
45
|
Merims S, Li X, Joe B, Dokouhaki P, Han M,
Childs RW, Wang ZY, Gupta V, Minden MD and Zhang L: Anti-leukemia
effect of ex vivo expanded DNT cells from AML patients: A potential
novel autologous T-cell adoptive immunotherapy. Leukemia.
25:1415–1422. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Voelkl S, Moore TV, Rehli M, Nishimura MI,
Mackensen A and Fischer K: Characterization of MHC class-I
restricted TCR+ CD4-CD8-double negative T cells recognizing the
gp100 antigen from a melanoma patient after gp100 vaccination.
Cancer Immunol Immunother. 58:709–718. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Qin Z, Richter G, Schüler T, Ibe S, Cao X
and Blankenstein T: B cells inhibit induction of T cell-dependent
tumor immunity. Nat Med. 4:627–630. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Shah S, Divekar AA, Hilchey SP, Cho HM,
Newman CL, Shin SU, Nechustan H, Challita-Eid PM, Segal BM, Yi KH
and Rosenblatt JD: Increased rejection of primary tumors in mice
lacking B cells: Inhibition of antitumor CTL and TH1 cytokine
responses by B cells. Int J Cancer. 117:574–586. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Lee-Chang C, Bodogai M, Martin-Montalvo A,
Wejksza K, Sanghvi M, Moaddel R, de Cabo R and Biragyn A:
Inhibition of breast cancer metastasis by resveratrol-mediated
inactivation of tumor-evoked regulatory B cells. J Immunol.
191:4141–4151. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Zhang Y, Eliav Y, Shin SU, Schreiber TH,
Podack ER, Tadmor T and Rosenblatt JD: B lymphocyte inhibition of
anti-tumor response depends on expansion of Treg but is independent
of B-cell IL-10 secretion. Cancer Immunol Immunother. 62:87–89.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Cunningham RC: Autoimmunity in primary
immune deficiency: Taking lessons from our patients. Clin Exp
Immunol. 164 Suppl 2:S6–S11. 2011. View Article : Google Scholar
|
|
52
|
Harris DP, Haynes L, Sayles PC, Duso DK,
Eaton SM, Lepak NM, Johnson LL, Swain SL and Lund FE: Reciprocal
regulation of polarized cytokine production by effector B and T
cells. Nat Immunol. 1:4752000. View
Article : Google Scholar : PubMed/NCBI
|
|
53
|
Olkhanud PB, Damdinsuren B, Bodogai M,
Gress RE, Sen R, Wejksza K, Wersto RP and Biragyn A: Tumor evoked
regulatory B cells promote breast cancer metastasis by converting
resting CD4+ T cells to T-regulatory cells. Cancer Res.
71:3505–3515. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Milne K, Köbel M, Kalloger SE, Barnes RO,
Gao D, Gilks CB, Watson PH and Nelson BH: Systematic analysis of
immune infiltrates in high-grade serous ovarian cancer reveals
CD20, FoxP3 and TIA-1 as positive prognostic factors. PLoS One.
4:e64122009. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Kobayashi T, Hamaguchi Y, Hasegawa M,
Fujimoto M, Takehara K and Matsushita T: B cells promote tumor
immunity against B16F10 melanoma. Am J Pathol. 184:3120–3129. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Fisher DT, Appenheimer MM and Evans SS:
The two faces of IL-6 in the tumor microenvironment. Semin Immunlo.
26:38–47. 2014. View Article : Google Scholar
|
|
57
|
Lippitz BE: Cytokine patterns in patients
with cancer: A systematic review. Lancet Oncol. 14:e218–e228. 2013.
View Article : Google Scholar : PubMed/NCBI
|
